Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Cisco Systems Inc (CSCO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Cisco Systems Inc — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.76 (market cap $4.49B), while Cisco Systems Inc trades at $113.71 (market cap $440.61B). The key difference: Cisco Systems Inc is far larger — about 98.1× ACADIA Pharmaceuticals Inc.'s market cap, and Cisco Systems Inc pays a 1.5% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | CSCO | |
|---|---|---|
Market Cap | $4.49B | $440.61B |
Sector | Health | Technology |
52-Week High | $28.06 | $130.00 |
52-Week Low | $20.06 | $66.20 |
Enterprise Value | $3.69B | $455.28B |
Volume | — | 22,887,319 |
Dividend Yield | — | 1.5% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
Cisco Systems (CSCO) trades at $113.98, up 1.14% on the day, with a technical picture showing bearish momentum indicators but recent positive earnings beats. The company reported Q1 2026 EPS of $1.06, beating expectations of $1.03, continuing a trend of outperformance. Recent news highlights Cisco's strategic push into AI cybersecurity, announcing new software tools and partnerships at Cisco Live 2026. Valuation metrics appear elevated with a P/E of 37.99 and P/S of 7.48, though profitability remains strong with a 64.33% gross margin.
The outlook balances strong analyst support (52% buy ratings with $130.38 consensus target) against high valuation multiples and mixed technical signals. Investment opportunity centers on Cisco's AI infrastructure and cybersecurity positioning, while risks include execution in transitioning growth drivers, competitive pressures, and potential margin compression if revenue growth slows.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Cisco Systems Inc
Cisco Systems, Inc. provides information technology and networking services. The Company offers enterprise network security, software development, data collaboration, cloud computing, and other related services. Cisco Systems serves customers in the United States.
Read more on CSCO →
